May 5, 2020 07:19 AM EDTUpdated 10:34 AM
Coronavirus

Covid-19 roundup: Pfiz­er, BioN­Tech start US hu­man tri­al; World lead­ers (not in­clud­ing the US) pledge $8 bil­lion in vac­cine, treat­ment re­search

Natalie Grover

Reporter

Last week, part­ners Pfiz­er and BioN­Tech joined the elite group of CanSi­no, Mod­er­na and Ox­ford who have be­gun hu­man tri­als of their …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

A service from the Financial Times